Maria Apellaniz-Ruiz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3418827/publications.pdf

Version: 2024-02-01

39 papers	1,113 citations	430874 18 h-index	395702 33 g-index
39 all docs	39 docs citations	39 times ranked	2233 citing authors

#	Article	IF	Citations
1	<scp>DICER1â€associated</scp> embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: Pathology, molecular genetics, and indications for molecular testing. Genes Chromosomes and Cancer, 2021, 60, 217-233.	2.8	29
2	Likely foregut endoderm origin for a postzygotic mutation affecting the RNase IIIb domain of DICER1. Journal of Medical Genetics, 2021, , jmedgenet-2021-107887.	3.2	0
3	The Value of DICER1 Mutation Analysis in â€œSubtleâ€•Diagnostically Challenging Embryonal Rhabdomyosarcomas of the Uterine Cervix. International Journal of Gynecological Pathology, 2021, 40, 435-440.	1.4	12
4	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics Journal, 2020, 20, 179-191.	2.0	7
5	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. Modern Pathology, 2020, 33, 1207-1219.	5.5	43
6	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. Lung Cancer, 2020, 147, 106-114.	2.0	5
7	Evaluation of molecular analysis in challenging ovarian sex cord-stromal tumours: a review of 50 cases. Pathology, 2020, 52, 686-693.	0.6	12
8	DICER1 screening in 15 paediatric paratesticular sarcomas unveils an unusual DICER1â€associated sarcoma. Journal of Pathology: Clinical Research, 2020, 6, 185-194.	3.0	11
9	A child with neuroblastoma and metachronous anaplastic sarcoma of the kidney: Underlying DICER1 syndrome?. Pediatric Blood and Cancer, 2020, 67, e28488.	1.5	2
10	Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube. American Journal of Surgical Pathology, 2020, 44, 738-747.	3.7	42
11	DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. Journal of Clinical Investigation, 2020, 130, 1479-1490.	8.2	31
12	RARE-22. GERMLINE PATHOGENIC VARIANT c.1552G>A;p.E518K IN DGCR8 CONFERS SUSCEPTIBILITY FOR SCHWANNOMATOSIS AND THYROID TUMORS. Neuro-Oncology, 2020, 22, iii447-iii447.	1.2	0
13	Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. New England Journal of Medicine, 2019, 380, 1834-1842.	27.0	39
14	A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Oncologist, 2019, 24, e1024-e1033.	3.7	16
15	Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy. Oncologist, 2019, 24, e784-e792.	3.7	20
16	Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 352-358.	4.9	18
17	Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients. Pharmacogenetics and Genomics, 2018, 28, 41-48.	1.5	13
18	Familial multinodular goiter and Sertoli-Leydig cell tumors associated with a large intragenic in-frame DICER1 deletion. European Journal of Endocrinology, 2018, 178, K11-K19.	3.7	20

#	Article	IF	Citations
19	A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation?. Pediatric Blood and Cancer, 2018, 65, e26715.	1.5	9
20	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. BMC Cancer, 2018, 18, 561.	2.6	13
21	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	1.5	5
22	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1310-1315.	4.9	16
23	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
24	Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer, 2017, 17, 63.	2.6	25
25	Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2017, 23, 1227-1235.	7.0	16
26	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 2017, 12, e0180192.	2.5	27
27	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics, 2016, 17, 463-471.	1.3	8
28	Human genetics: international projects and personalized medicine. Drug Metabolism and Personalized Therapy, 2016, 31, 3-8.	0.6	10
29	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight, 2016, 1, e86051.	5.0	39
30	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelâ€"Letter. Clinical Cancer Research, 2015, 21, 3092-3093.	7.0	9
31	Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Research and Treatment, 2015, 149, 385-394.	2.5	27
32	Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene. Journal of the National Cancer Institute, 2015, 107, .	6.3	143
33	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, 2015, 26, 1987-1993.	1.2	112
34	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
35	Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. Journal of Medical Genetics, 2015, 52, 647-656.	3.2	102
36	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, 16, 929-937.	1.3	17

#	Article	IF	Citations
37	Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. Clinical Cancer Research, 2015, 21, 322-328.	7.0	61
38	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics Journal, 2015, 15, 288-292.	2.0	48
39	VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma. Thyroid, 2014, 24, 1251-1255.	4.5	18